top of page
Search

THE HRT BLACK BOX WARNING CHANGED: WHAT THE FDA DID AND WHAT IT MEANS FOR YOU

Writer: Elaine Burris, APRN, FNP-C
Elaine Burris, APRN, FNP-C
4 minutes ago
8 min read
Hormone therapy FDA black box warning changed

The HRT black box warning on menopause hormone therapy is being rewritten: on November 10, 2025, the FDA asked the makers of every menopausal hormone product to remove the boxed warnings about heart disease, breast cancer, and probable dementia. In February 2026 it approved the first six revised labels. The risks themselves have not disappeared from the labels. They move out of the box and into the standard warnings section, and one boxed warning stays for some women. If you have been weighing hormone therapy and the warning held you back, here is what changed and how to think about it.


By Elaine Burris, APRN, FNP-C, Wellness Nurse Practitioner, Hartwater Wellness


Medically reviewed by Scott Bradley Burris, MD, Medical Director and board-certified anesthesiologist. Reviewed October 2026.


THE SHORT ANSWER


  • What was removed from the box: the warnings about cardiovascular disease, breast cancer, and probable dementia, plus the boxed advice to use "the lowest effective dose for the shortest amount of time."

  • What stays in the box: the endometrial cancer warning, for systemic estrogen-only products in women who have a uterus.

  • What stays in the label: heart and breast cancer risks remain in the Warnings and Precautions section, and the list of women who should not take estrogen is unchanged.

  • What is new: labels for systemic products now say to consider starting therapy for moderate to severe hot flashes and night sweats in women under 60 or within 10 years of menopause.

  • What it does not cover: compounded hormones, including compounded estradiol pellets, which have no FDA label to change.

  • Timing: many brand labels have not been revised yet, so the product in your medicine cabinet may still show the old box.


WHERE THE HRT BLACK BOX WARNING CAME FROM


The warning traces back to the Women's Health Initiative, a large federal trial stopped early in 2002. Its estrogen-plus-progestin arm gave more than 16,000 women a combination of conjugated equine estrogens (made from pregnant horses' urine) and medroxyprogesterone acetate, a synthetic progestin, or a placebo. Breast cancer rose (a hazard ratio of 1.26, or about 8 extra cases per 10,000 women per year), along with heart disease, stroke, and blood clots. Hip fractures and colorectal cancer fell.


Two details shaped how the findings were later read:


  • The women were older. The average participant was about 63, more than a decade past the typical age of menopause, and most were not starting hormones for hot flashes.

  • Estrogen alone behaved differently. In the trial's estrogen-only arm (women who had had a hysterectomy), breast cancer did not rise. After 20 years of follow-up, those women had significantly fewer breast cancer diagnoses and deaths than the placebo group.


Follow-up studies added the timing piece. Over 18 years of WHI follow-up, overall death rates were the same with hormones as with placebo, and the comparison favored women who started in their 50s over women who started in their 70s. In the ELITE trial, estradiol slowed the thickening of artery walls when started within six years of menopause, with no effect when started ten or more years later.


After 2002, prescriptions fell sharply, and the boxed warning applied the WHI's older-women results to every woman considering treatment. The FDA cited that mismatch when it announced the change.


WHAT THE FDA CHANGED IN THE HRT BLACK BOX WARNING


The table lays out the HRT black box warning before and after the revision, using the FDA's own list of requested changes.



The first six revised labels, approved February 12, 2026, were Prometrium (micronized progesterone), Divigel (estradiol gel), Cenestin, Enjuvia, Bijuva, and Estring. Twenty-nine companies were asked to submit changes. As of October 2026, several widely used labels still carry the older four-part box, so a label you read at the pharmacy may not match this article yet.


WHAT DID NOT CHANGE


The revision moved the risk information to a different part of the label, where it remains.


  • Breast cancer and heart risks stay in the label, in the Warnings and Precautions section, where they are described in proportion to the evidence.

  • The endometrial cancer boxed warning stays for systemic estrogen-only products. Estrogen alone thickens the lining of the uterus, which is why a woman with a uterus takes progesterone alongside estrogen.

  • The contraindications are unchanged. Estrogen therapy is still not appropriate for women with unexplained vaginal bleeding, current or past breast cancer, estrogen-dependent tumors, a current or past blood clot in the legs or lungs, a past stroke or heart attack, liver disease, or certain inherited clotting disorders.

  • Dosing still starts low. The revised labels drop the boxed "lowest dose, shortest time" rule, but they still tell clinicians to begin at the lowest effective dose and reassess regularly.


The Menopause Society welcomed the change for low-dose vaginal estrogen and noted that systemic estrogen "still comes with potential risks in certain individuals." Its 2022 position statement remains the best summary: for women under 60 or within 10 years of menopause who have no contraindications, the benefits of hormone therapy outweigh the risks for treating hot flashes and night sweats and for preventing bone loss. For women who start later, the balance is less favorable.


WHAT THIS MEANS FOR BIOIDENTICAL HORMONES AND PELLETS


The label change applies to FDA-approved products. Several of those are bioidentical, meaning molecularly identical to the hormones a woman's body makes: estradiol in patches, gels, and pills, and micronized progesterone (Prometrium, one of the first six revised labels).


Compounded hormones are made by pharmacies or outsourcing facilities without going through the FDA's drug approval process, so there is no FDA label to revise. That includes estradiol pellets: no estradiol pellet is FDA-approved in the United States. The American College of Obstetricians and Gynecologists stated on November 10, 2025 that compounded estrogen products "are not subject to the HHS announcement" and that it continues to recommend against them. A 2020 National Academies report reached a similar conclusion, recommending compounded hormones only when a patient needs a dose or form no approved product offers or is allergic to an ingredient in one.


Where a pellet is made matters. Compounded pellets come from two kinds of sources, and federal law treats them differently. A 503A compounding pharmacy prepares medications under its state board of pharmacy and the USP standards for sterile compounding. An FDA-registered 503B outsourcing facility makes medications in batches under the FDA's current good manufacturing practice rules, the quality system that applies to drug manufacturers, which require testing of finished batches before release. Outsourcing facilities are inspected by the FDA and must report serious adverse events to it. Hartwater Wellness uses EvexiPEL pellets from EVEXIAS Health Solutions, which are made in an FDA-registered 503B outsourcing facility. We chose that source for its manufacturing standards and batch-to-batch consistency. Pellets from either kind of source are compounded drugs, and neither is FDA-approved.


Here is how we apply that at Hartwater Wellness. Every option we offer uses bioidentical estradiol, progesterone, or testosterone, and pellets are one delivery method among several. Some women prefer pellets because they release a steady dose over three to four months with nothing to apply each day. Others do better with an FDA-approved patch, gel, or oral progesterone. We review the evidence for each with you, including the regulatory difference between approved and compounded products, and match the method to your history, your lab values, and your preference. Progesterone, when you need it, is given separately as an oral capsule or cream because it does not work well in pellet form. That matters for anyone choosing among them: in the large French E3N study, estrogen combined with micronized progesterone showed no increase in breast cancer risk, while estrogen combined with synthetic progestins did. E3N was an observational study, so it shows an association and cannot prove cause.


WHO IS A GOOD CANDIDATE NOW


The label change makes one group's decision clearer: women under 60, or within 10 years of their last period, with moderate to severe hot flashes or night sweats and no contraindications. Hot flashes affect up to 85% of women in the menopause transition, and for many the symptoms disrupt sleep, mood, and work for years.


Hormone therapy remains a medical decision, made one woman at a time. Your personal and family history of breast cancer, blood clots, stroke, and heart disease still matters. So do your blood pressure, your liver function, and how long it has been since your last period. Women who start more than 10 years after menopause can still be candidates, with a more careful look at cardiovascular risk.


HOW WE APPROACH HORMONE THERAPY AT HARTWATER WELLNESS


Hormone Optimization is one of the nine health categories every Hartwater Wellness assessment ranks, and for many women in their 40s and 50s it comes out near the top. We start with measurement:


  • Hormone Baseline lab panel ($350) before any therapy, so dosing is based on your measured levels.

  • A plan built around your symptoms and history, with the delivery method chosen together.

  • Follow-up labs after starting (a post-pellet panel is $99) and monitoring every three to four months for women on pellets, with Scott Bradley Burris, MD overseeing every protocol.


Hormone pellet insertions are $399 for women. Other hormone protocols are quoted at your consultation, because the cost depends on the medication and dose. Hartwater Wellness is a cash-pay practice; HSA and FSA accepted. Hormone therapy is also one piece of a broader plan, which can include our longevity lab panels for bone, metabolic, and cardiovascular markers.


FREQUENTLY ASKED QUESTIONS


Did the FDA remove the black box warning on estrogen?


Mostly. The FDA requested removal of the boxed warnings on heart disease, breast cancer, and probable dementia for all menopausal hormone products. The endometrial cancer boxed warning remains for systemic estrogen-only products. Labels are being revised in batches, starting with six approved on February 12, 2026.


Is hormone therapy safe now?


For healthy women under 60 or within 10 years of menopause, major medical societies consider the benefits greater than the risks for treating hot flashes and night sweats. The risks have not changed; the label now describes them in proportion to the evidence. Safety still depends on your personal history, the type of hormone, the dose, and the route.


Does HRT cause breast cancer?


It depends on the regimen. In the Women's Health Initiative, estrogen combined with a synthetic progestin modestly increased breast cancer, while estrogen alone did not, and over 20 years it was linked to fewer breast cancer cases. Observational data suggest micronized progesterone carries less risk than synthetic progestins.


Is it too late to start hormone therapy after 60?


Not necessarily, but the balance of benefit and risk is less favorable when therapy starts after 60 or more than 10 years after menopause, mainly because heart disease, stroke, and blood clot risks are higher. A careful review of your cardiovascular health comes first.


Does the label change apply to hormone pellets?


No. The change applies to FDA-approved products. Compounded hormones, including estradiol pellets, are not FDA-approved and have no FDA label. FDA-approved bioidentical options, such as estradiol patches and gels and micronized progesterone, are covered.


SCHEDULE A CONSULTATION


If menopause symptoms are affecting your sleep, mood, or work, a consultation is the place to sort out whether hormone therapy fits your history. Hartwater Wellness is a physician-led practice at 7200 West University Drive, Suite 170, in McKinney, serving Frisco, Allen, Prosper, Plano, Celina, and Collin County. Schedule online or call (469) 678-8748.


SOURCES


bottom of page